You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBenzphetamine
Accession NumberDB00865  (APRD00759)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Structure
Thumb
Synonyms
(+)-benzphetamine
(+)-N-Benzyl-N,alpha-dimethylphenethylamine
(+)-N-benzyl-N,α-dimethylphenethylamine
(+)-N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine
(+)-N,α-dimethyl-N-(phenylmethyl)-benzeneethanamine
(AlphaS)-N,alpha-dimethylphenethylamine
(S)-(+)-benzphetamine
(S)-(+)-N-Benzyl-N,alpha-dimethylphenethylamine
(S)-(+)-N-benzyl-N,α-dimethylphenethylamine
(S)-benzphetamine
Benzaphetamine
Benzfetamina
Benzfetamine
Benzfetaminum
Benzphetamine
Benzylamphetamine
D-N-Methyl-N-benzyl-beta-phenylisopropylamine
d-N-methyl-N-benzyl-β-phenylisopropylamine
N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DidrexTablet50 mg/1OralA S Medication Solutions Llc1960-10-26Not applicableUs
DidrexTablet50 mg/1OralA S Medication Solutions Llc1960-10-26Not applicableUs
DidrexTablet50 mg/1OralPd Rx Pharmaceuticals, Inc.1960-10-26Not applicableUs
DidrexTablet50 mg/1OralPharmacia and Upjohn Company1960-10-262015-12-29Us
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BenzphetamineTablet25 mg/1OralTedor Pharma Inc.2016-02-01Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralPd Rx Pharmaceuticals, Inc.2011-11-01Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2008-12-012016-11-15Us
Benzphetamine HydrochlorideTablet50 mg/1OralBoca Pharmacal, LLC2010-09-07Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralA S Medication Solutions Llc2010-07-21Not applicableUs
Benzphetamine HydrochlorideTablet, film coated50 mg/1OralHeritage Pharmaceuticals Inc.2012-10-19Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralPd Rx Pharmaceuticals, Inc.2010-07-21Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralC.O. Truxton, Inc.2011-11-01Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralA S Medication Solutions Llc2010-07-21Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralAidarex Pharmaceuticals LLC2010-07-21Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralSolco Healthcare US LLC2011-08-01Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralKvk Tech, Inc2010-07-21Not applicableUs
Benzphetamine HydrochlorideTablet25 mg/1OralNivagen Pharmaceuticals, Inc.2016-01-15Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralPd Rx Pharmaceuticals, Inc.2009-12-09Not applicableUs
Benzphetamine HydrochlorideTablet, film coated50 mg/1OralEpic Pharma, LLC2015-12-16Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralMikart, Inc.2011-11-01Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralApotheca Inc.2009-12-09Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralNivagen Pharmaceuticals, Inc.2016-01-15Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1Oralbryant ranch prepack2010-02-01Not applicableUs
RegimexTablet25 mg/1OralWraser Pharmaceuticals2013-02-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Benzphetamine Hydrochloride
Thumb
  • InChI Key: ANFSNXAXVLRZCG-UHFFFAOYNA-N
  • Monoisotopic Mass: 275.144077416
  • Average Mass: 275.816
DBSALT000832
Categories
UNII0M3S43XK27
CAS number156-08-1
WeightAverage: 239.3553
Monoisotopic: 239.167399677
Chemical FormulaC17H21N
InChI KeyYXKTVDFXDRQTKV-HNNXBMFYSA-N
InChI
InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
IUPAC Name
benzyl(methyl)[(2S)-1-phenylpropan-2-yl]amine
SMILES
C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1
Pharmacology
IndicationFor the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction
Structured Indications
PharmacodynamicsBenzphetamine, a phenylalkylamin, is related to amphetamine both chemically and pharmacologically. It is an anorectic agent indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. Benzphetamine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
Mechanism of actionAlthough the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated by the binding of benzphetamine to centrally located adrenergic receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Synaptic vesicular amine transporterProteinyes
inducer
HumanQ05940 details
Alpha-2A adrenergic receptorProteinyes
agonist
HumanP08913 details
Alpha-1A adrenergic receptorProteinyes
agonist
HumanP35348 details
Sodium-dependent dopamine transporterProteinunknown
inhibitor
HumanQ01959 details
Related Articles
AbsorptionReadily absorbed from the gastro-intestinal tract and buccal mucosa. It Is resistant to metabolism by monoamine oxidase.
Volume of distributionNot Available
Protein binding75-99%
Metabolism

Hepatic. Benzphetamine's metabolites include amphetamine and methamphetamine.

SubstrateEnzymesProduct
Benzphetamine
Not Available
AmphetamineDetails
Benzphetamine
Not Available
MethamphetamineDetails
Route of eliminationNot Available
Half life16 to 31 hours
ClearanceNot Available
ToxicityLD50=160 mg/kg (orally in rats). Acute overdosage may result in restlessness, tremor, tachypnea, confusion, assaultiveness, and panic states.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Benzphetamine.Experimental
AcebutololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Benzphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Benzphetamine.Approved
AcrivastineBenzphetamine may decrease the sedative activities of Acrivastine.Approved
AlcaftadineBenzphetamine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilBenzphetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlimemazineBenzphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlphacetylmethadolBenzphetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlprenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
Aluminum phosphateAluminum phosphate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Benzphetamine.Illicit, Withdrawn
AmiodaroneThe metabolism of Benzphetamine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Benzphetamine.Approved
Ammonium chlorideThe serum concentration of Benzphetamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Benzphetamine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Benzphetamine.Approved, Illicit
AntazolineBenzphetamine may decrease the sedative activities of Antazoline.Approved
Aop200704Benzphetamine may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
AprepitantThe serum concentration of Benzphetamine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
ArotinololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
AsenapineAsenapine may decrease the stimulatory activities of Benzphetamine.Approved
AstemizoleBenzphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Benzphetamine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Benzphetamine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Benzphetamine.Vet Approved
AzatadineBenzphetamine may decrease the sedative activities of Azatadine.Approved
AzelastineBenzphetamine may decrease the sedative activities of Azelastine.Approved
BefunololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Benzphetamine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Benzphetamine.Investigational
BetaxololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BexaroteneThe serum concentration of Benzphetamine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideBenzphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Benzphetamine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
BisoprololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BoceprevirThe metabolism of Benzphetamine can be decreased when combined with Boceprevir.Approved
BopindololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Benzphetamine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Benzphetamine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Benzphetamine.Approved
BromperidolBromperidol may decrease the stimulatory activities of Benzphetamine.Investigational
BrompheniramineBenzphetamine may decrease the sedative activities of Brompheniramine.Approved
BucindololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BuclizineBenzphetamine may decrease the sedative activities of Buclizine.Approved
BufuralolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupranololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineBenzphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
Butanoic AcidBenzphetamine may decrease the sedative activities of Butanoic Acid.Experimental
ButorphanolBenzphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium carbonateCalcium carbonate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
CarbamazepineThe metabolism of Benzphetamine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineBenzphetamine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilBenzphetamine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Benzphetamine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Benzphetamine.Withdrawn
CarteololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Benzphetamine can be increased when it is combined with Ceritinib.Approved
CetirizineBenzphetamine may decrease the sedative activities of Cetirizine.Approved
ChloropyramineBenzphetamine may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineBenzphetamine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineBenzphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Benzphetamine.Approved, Withdrawn
CimetidineBenzphetamine may decrease the sedative activities of Cimetidine.Approved
CinnarizineBenzphetamine may decrease the sedative activities of Cinnarizine.Approved
CitalopramThe metabolism of Benzphetamine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Benzphetamine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Benzphetamine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Clenbuterol.Approved, Vet Approved
ClomipramineClomipramine may decrease the antihypertensive activities of Benzphetamine.Approved, Vet Approved
ClopidogrelThe metabolism of Benzphetamine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Benzphetamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may decrease the stimulatory activities of Benzphetamine.Approved
CobicistatThe metabolism of Benzphetamine can be decreased when combined with Cobicistat.Approved
CodeineBenzphetamine may increase the analgesic activities of Codeine.Approved, Illicit
ConivaptanThe serum concentration of Benzphetamine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Benzphetamine can be decreased when combined with Crizotinib.Approved
CyamemazineCyamemazine may decrease the stimulatory activities of Benzphetamine.Approved
CyclizineBenzphetamine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Benzphetamine.Approved
CyclosporineThe metabolism of Benzphetamine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineBenzphetamine may decrease the sedative activities of Cyproheptadine.Approved
DabrafenibThe serum concentration of Benzphetamine can be decreased when it is combined with Dabrafenib.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Benzphetamine.Approved
DarunavirThe metabolism of Benzphetamine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Benzphetamine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Benzphetamine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Benzphetamine can be decreased when combined with Delavirdine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Benzphetamine.Approved
DesloratadineBenzphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Benzphetamine.Approved
DexamethasoneThe serum concentration of Benzphetamine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineBenzphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine maleateBenzphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideBenzphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneBenzphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineBenzphetamine may increase the analgesic activities of Dezocine.Approved
DiclofenamideDiclofenamide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
DihydrocodeineBenzphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Benzphetamine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineBenzphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineBenzphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Benzphetamine can be decreased when combined with Diltiazem.Approved
DimenhydrinateBenzphetamine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneBenzphetamine may decrease the sedative activities of Dimetindene.Approved
DimetotiazineBenzphetamine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineBenzphetamine may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylateBenzphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Benzphetamine.Approved
DopamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dopamine.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Benzphetamine.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Benzphetamine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Doxofylline.Approved
DoxorubicinThe metabolism of Benzphetamine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Benzphetamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineBenzphetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEBenzphetamine may increase the analgesic activities of DPDPE.Investigational
DronabinolDronabinol may increase the tachycardic activities of Benzphetamine.Approved, Illicit
DronedaroneThe metabolism of Benzphetamine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
DuloxetineDuloxetine may decrease the antihypertensive activities of Benzphetamine.Approved
EbastineBenzphetamine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Benzphetamine.Investigational
EfavirenzThe serum concentration of Benzphetamine can be decreased when it is combined with Efavirenz.Approved, Investigational
EmedastineBenzphetamine may decrease the sedative activities of Emedastine.Approved
EnzalutamideThe serum concentration of Benzphetamine can be decreased when it is combined with Enzalutamide.Approved
EphedrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Ephedrine.Approved
EpinastineBenzphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Benzphetamine.Approved, Vet Approved
ErythromycinThe metabolism of Benzphetamine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Benzphetamine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Benzphetamine.Investigational
EsmololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EthopropazineBenzphetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Benzphetamine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Withdrawn
EthylmorphineBenzphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Etilefrine.Withdrawn
EtorphineBenzphetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Benzphetamine can be decreased when it is combined with Etravirine.Approved
FamotidineBenzphetamine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Fenoterol.Approved
FentanylBenzphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineBenzphetamine may decrease the sedative activities of Fexofenadine.Approved
FluconazoleThe metabolism of Benzphetamine can be decreased when combined with Fluconazole.Approved
FlunarizineBenzphetamine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Benzphetamine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Benzphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Benzphetamine.Approved
FluvoxamineThe metabolism of Benzphetamine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Benzphetamine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Benzphetamine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Benzphetamine can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Benzphetamine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Benzphetamine can be increased when it is combined with Fusidic Acid.Approved
GuanethidineThe serum concentration of Benzphetamine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Benzphetamine.Approved
HeroinBenzphetamine may increase the analgesic activities of Heroin.Approved, Illicit
HexamethylenetetramineThe serum concentration of Benzphetamine can be decreased when it is combined with Hexamethylenetetramine.Approved, Vet Approved
HydracarbazineHydracarbazine may increase the hypertensive activities of Benzphetamine.Approved
HydrocodoneBenzphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneBenzphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Hydroxyamphetamine hydrobromide.Approved
HydroxyzineBenzphetamine may decrease the sedative activities of Hydroxyzine.Approved
IdelalisibThe serum concentration of Benzphetamine can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Benzphetamine.Approved
ImatinibThe metabolism of Benzphetamine can be decreased when combined with Imatinib.Approved
ImipramineImipramine may decrease the antihypertensive activities of Benzphetamine.Approved
IndenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe metabolism of Benzphetamine can be decreased when combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Benzphetamine.Approved
Ioflupane I-123Benzphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the hypertensive activities of Benzphetamine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Benzphetamine.Withdrawn
IsavuconazoniumThe metabolism of Benzphetamine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Benzphetamine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Isoprenaline.Approved
IsothipendylBenzphetamine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Benzphetamine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Benzphetamine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Benzphetamine can be increased when it is combined with Ivacaftor.Approved
Kct 0809Benzphetamine may decrease the sedative activities of Kct 0809.Investigational
KetobemidoneBenzphetamine may increase the analgesic activities of Ketobemidone.Approved
KetoconazoleThe metabolism of Benzphetamine can be decreased when combined with Ketoconazole.Approved, Investigational
KetotifenBenzphetamine may decrease the sedative activities of Ketotifen.Approved
L-Glutamic AcidThe serum concentration of Benzphetamine can be decreased when it is combined with L-Glutamic Acid.Nutraceutical
LabetalolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LevocabastineBenzphetamine may decrease the sedative activities of Levocabastine.Approved
LevocetirizineBenzphetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateBenzphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Benzphetamine.Approved
LevorphanolBenzphetamine may increase the analgesic activities of Levorphanol.Approved
LinezolidLinezolid may increase the hypertensive activities of Benzphetamine.Approved, Investigational
LithiumLithium may decrease the stimulatory activities of Benzphetamine.Approved
LodoxamideBenzphetamine may decrease the sedative activities of Lodoxamide.Approved
LofentanilBenzphetamine may increase the analgesic activities of Lofentanil.Illicit
LopinavirThe metabolism of Benzphetamine can be decreased when combined with Lopinavir.Approved
LoratadineBenzphetamine may decrease the sedative activities of Loratadine.Approved
LovastatinThe metabolism of Benzphetamine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may decrease the stimulatory activities of Benzphetamine.Approved
LuliconazoleThe serum concentration of Benzphetamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Benzphetamine can be decreased when it is combined with Lumacaftor.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Benzphetamine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Withdrawn
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Benzphetamine.Withdrawn
MeclizineBenzphetamine may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of Benzphetamine.Approved
MephentermineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Mephentermine.Approved
MepyramineBenzphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineBenzphetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Benzphetamine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Benzphetamine.Approved, Investigational
MethadoneBenzphetamine may increase the analgesic activities of Methadone.Approved
Methadyl AcetateBenzphetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Methamphetamine.Approved, Illicit
MethapyrileneBenzphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Benzphetamine.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Benzphetamine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Benzphetamine.Investigational
MetiamideBenzphetamine may decrease the sedative activities of Metiamide.Experimental
MetoprololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MianserinThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Mianserin.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Benzphetamine.Approved
MifepristoneThe serum concentration of Benzphetamine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may decrease the antihypertensive activities of Benzphetamine.Approved
MinaprineMinaprine may increase the hypertensive activities of Benzphetamine.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Benzphetamine.Approved
MitotaneThe serum concentration of Benzphetamine can be decreased when it is combined with Mitotane.Approved
MizolastineBenzphetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Benzphetamine.Approved
ModafinilThe serum concentration of Benzphetamine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneMolindone may decrease the stimulatory activities of Benzphetamine.Approved
MorphineBenzphetamine may increase the analgesic activities of Morphine.Approved, Investigational
NabiloneNabilone may increase the tachycardic activities of Benzphetamine.Approved, Investigational
NadololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NafcillinThe serum concentration of Benzphetamine can be decreased when it is combined with Nafcillin.Approved
NalbuphineBenzphetamine may increase the analgesic activities of Nalbuphine.Approved
NefazodoneThe metabolism of Benzphetamine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Benzphetamine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Benzphetamine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Benzphetamine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypertensive activities of Benzphetamine.Withdrawn
NilotinibThe metabolism of Benzphetamine can be decreased when combined with Nilotinib.Approved, Investigational
NizatidineBenzphetamine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Benzphetamine.Approved
NormethadoneBenzphetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Benzphetamine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Benzphetamine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
OlaparibThe metabolism of Benzphetamine can be decreased when combined with Olaparib.Approved
OlopatadineBenzphetamine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Benzphetamine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Benzphetamine.Investigational
OpiumBenzphetamine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Benzphetamine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Benzphetamine.Investigational
OsimertinibThe serum concentration of Benzphetamine can be increased when it is combined with Osimertinib.Approved
OxprenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxycodoneBenzphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Oxymetazoline.Approved
OxymorphoneBenzphetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Benzphetamine can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may decrease the stimulatory activities of Benzphetamine.Approved
PargylinePargyline may increase the hypertensive activities of Benzphetamine.Approved
ParoxetineThe metabolism of Benzphetamine can be decreased when combined with Paroxetine.Approved, Investigational
PemirolastBenzphetamine may decrease the sedative activities of Pemirolast.Approved
PenbutololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentazocineBenzphetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Benzphetamine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Benzphetamine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Benzphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Benzphetamine.Approved
PethidineBenzphetamine may increase the analgesic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Benzphetamine.Approved
PhenindamineBenzphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Benzphetamine.Withdrawn
PheniramineBenzphetamine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Benzphetamine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Benzphetamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Benzphetamine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Benzphetamine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Benzphetamine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Benzphetamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Benzphetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Benzphetamine.Approved
PindololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperonePipamperone may decrease the stimulatory activities of Benzphetamine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Benzphetamine.Approved
PiritramideBenzphetamine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Benzphetamine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Benzphetamine.Withdrawn
PosaconazoleThe metabolism of Benzphetamine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrimidoneThe metabolism of Benzphetamine can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Procaterol.Approved
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
PromethazineBenzphetamine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Benzphetamine.Approved
PropranololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProthipendylProthipendyl may decrease the stimulatory activities of Benzphetamine.Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Benzphetamine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Pseudoephedrine.Approved
QuazepamThe serum concentration of Benzphetamine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineQuetiapine may decrease the stimulatory activities of Benzphetamine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Benzphetamine.Investigational
RanitidineBenzphetamine may decrease the sedative activities of Ranitidine.Approved
RanolazineThe metabolism of Benzphetamine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypertensive activities of Benzphetamine.Approved
RemifentanilBenzphetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Benzphetamine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Benzphetamine.Approved
RifabutinThe metabolism of Benzphetamine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Benzphetamine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Benzphetamine can be increased when combined with Rifapentine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Benzphetamine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Ritodrine.Approved
RitonavirThe metabolism of Benzphetamine can be decreased when combined with Ritonavir.Approved, Investigational
Roxatidine acetateBenzphetamine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Benzphetamine.Withdrawn
SaquinavirThe metabolism of Benzphetamine can be decreased when combined with Saquinavir.Approved, Investigational
SelegilineSelegiline may increase the hypertensive activities of Benzphetamine.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Benzphetamine.Approved, Withdrawn
SertralineThe metabolism of Benzphetamine can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Benzphetamine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Benzphetamine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Benzphetamine can be increased when it is combined with Simeprevir.Approved
SorafenibThe metabolism of Benzphetamine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
Spaglumic AcidBenzphetamine may decrease the sedative activities of Spaglumic Acid.Approved
St. John's WortThe serum concentration of Benzphetamine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Benzphetamine can be increased when it is combined with Stiripentol.Approved
SufentanilBenzphetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Benzphetamine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may decrease the stimulatory activities of Benzphetamine.Approved
SynephrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Synephrine.Experimental
TapentadolBenzphetamine may increase the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Benzphetamine.Approved
TelaprevirThe metabolism of Benzphetamine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Benzphetamine can be decreased when combined with Telithromycin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Terbutaline.Approved
TerfenadineBenzphetamine may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifeneBenzphetamine may decrease the sedative activities of Tesmilifene.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tetryzoline.Approved
ThioproperazineThioproperazine may decrease the stimulatory activities of Benzphetamine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Benzphetamine.Approved
ThiotepaThe metabolism of Benzphetamine can be decreased when combined with Thiotepa.Approved
ThiothixeneThiothixene may decrease the stimulatory activities of Benzphetamine.Approved
ThonzylamineBenzphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Benzphetamine.Approved
TiaprideTiapride may decrease the stimulatory activities of Benzphetamine.Investigational
TiclopidineThe metabolism of Benzphetamine can be decreased when combined with Ticlopidine.Approved
TimololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TocilizumabThe serum concentration of Benzphetamine can be decreased when it is combined with Tocilizumab.Approved
ToloxatoneToloxatone may increase the hypertensive activities of Benzphetamine.Approved
TramadolBenzphetamine may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastBenzphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Benzphetamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Benzphetamine.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Benzphetamine.Approved
TriflupromazineTriflupromazine may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Benzphetamine.Approved
TripelennamineBenzphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineBenzphetamine may decrease the sedative activities of Triprolidine.Approved
TyramineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tyramine.Investigational, Nutraceutical
VenlafaxineThe metabolism of Benzphetamine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Benzphetamine can be decreased when combined with Verapamil.Approved
Vitamin CThe serum concentration of Benzphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
VoriconazoleThe metabolism of Benzphetamine can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Benzphetamine can be decreased when combined with Ziprasidone.Approved
ZotepineZotepine may decrease the stimulatory activities of Benzphetamine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Dennis J. Kalota, Keith G. Tomazi, “Crystallization Method for Benzphetamine.” U.S. Patent US20080262268, issued October 23, 2008.

US20080262268
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (16.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9933
Blood Brain Barrier+0.9864
Caco-2 permeable+0.8815
P-glycoprotein substrateSubstrate0.541
P-glycoprotein inhibitor INon-inhibitor0.8803
P-glycoprotein inhibitor IINon-inhibitor0.9437
Renal organic cation transporterInhibitor0.7013
CYP450 2C9 substrateNon-substrate0.769
CYP450 2D6 substrateNon-substrate0.588
CYP450 3A4 substrateNon-substrate0.5135
CYP450 1A2 substrateInhibitor0.8684
CYP450 2C9 inhibitorNon-inhibitor0.9146
CYP450 2D6 inhibitorInhibitor0.539
CYP450 2C19 inhibitorNon-inhibitor0.5997
CYP450 3A4 inhibitorNon-inhibitor0.8789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8047
Ames testNon AMES toxic0.888
CarcinogenicityNon-carcinogens0.6584
BiodegradationNot ready biodegradable0.9825
Rat acute toxicity3.1442 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8779
hERG inhibition (predictor II)Non-inhibitor0.5331
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Corepharma llc
  • Impax laboratories inc
  • Kvk tech inc
  • Paddock laboratories inc
  • Tedor pharma inc
  • Tyco healthcare mallinckrodt
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
TabletOral50 mg/1
Tablet, film coatedOral50 mg/1
TabletOral25 mg/1
Prices
Unit descriptionCostUnit
Didrex 50 mg tablet1.71USD tablet
Benzphetamine hcl 50 mg tablet1.43USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point129-130Heinzelman, R.V. and Aspergren, B.D.; US. Patent 2,789,138; April 16,1957; assigned to The Upjohn Company.
water solubilityReadily solubleNot Available
logP4.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0233 mg/mLALOGPS
logP3.72ALOGPS
logP4.34ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity78.39 m3·mol-1ChemAxon
Polarizability29.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.86 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene Name:
SLC18A2
Uniprot ID:
Q05940
Molecular Weight:
55712.075 Da
References
  1. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A: Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995 May;15(5 Pt 2):4102-8. [PubMed:7751968 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613 ]
  2. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A: Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3495-500. Epub 2005 Feb 22. [PubMed:15728379 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA: Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75. [PubMed:8486332 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Bumpus NN, Sridar C, Kent UM, Hollenberg PF: The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos. 2005 Jun;33(6):795-802. Epub 2005 Mar 15. [PubMed:15769884 ]
  2. Shebley M, Kent UM, Ballou DP, Hollenberg PF: Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52. doi: 10.1124/dmd.108.024661. Epub 2009 Jan 14. [PubMed:19144770 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
Gene Name:
POR
Uniprot ID:
P16435
Molecular Weight:
76689.12 Da
References
  1. Kanaeva IP, Nikityuk OV, Davydov DR, Dedinskii IR, Koen YM, Kuznetsova GP, Skotselyas ED, Bachmanova GI, Archakov AI: Comparative study of monomeric reconstituted and membrane microsomal monooxygenase systems of the rabbit liver. II. Kinetic parameters of reductase and monooxygenase reactions. Arch Biochem Biophys. 1992 Nov 1;298(2):403-12. [PubMed:1416971 ]
  2. Matsumoto T, Emi Y, Kawabata S, Omura T: Purification and characterization of three male-specific and one female-specific forms of cytochrome P-450 from rat liver microsomes. J Biochem. 1986 Nov;100(5):1359-71. [PubMed:2434473 ]
  3. Kojima H, Takahashi K, Sakane F, Koyama J: Purification and characterization of NADPH-cytochrome c reductase from porcine polymorphonuclear leukocytes. J Biochem. 1987 Nov;102(5):1083-8. [PubMed:3125159 ]
  4. Dutton DR, McMillen SK, Parkinson A: Purification of rat liver microsomal cytochrome P-450b without the use of nonionic detergent. J Biochem Toxicol. 1988 Summer;3:131-45. [PubMed:3148724 ]
  5. Halpert JR, Miller NE, Gorsky LD: On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403. [PubMed:3924914 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23